The FDA approved Guardant Health’s upgraded Guardant360 Liquid CDx, expanding the test’s genomic and epigenomic coverage for comprehensive tumor profiling from a single blood draw. The new assay is described as analyzing a 100-fold larger footprint than the previously approved version, and the seven companion diagnostic indications tied to the older test are set to transfer to the new platform. The approval strengthens Guardant’s position in advanced cancer decision support by enabling broader interrogation of biomarkers relevant to targeted therapy selection. Analysts highlighted the potential for faster uptake in advanced diagnostic laboratory testing and the impact this could have on pricing and revenue cadence. —